XTX Topco Ltd Takes Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

XTX Topco Ltd acquired a new position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 13,278 shares of the biopharmaceutical company’s stock, valued at approximately $75,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. SageView Advisory Group LLC bought a new stake in shares of Vanda Pharmaceuticals during the first quarter worth $34,000. Meeder Asset Management Inc. acquired a new stake in shares of Vanda Pharmaceuticals during the 2nd quarter valued at $39,000. China Universal Asset Management Co. Ltd. increased its holdings in Vanda Pharmaceuticals by 65.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,045 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 4,387 shares in the last quarter. SG Americas Securities LLC bought a new position in Vanda Pharmaceuticals in the second quarter valued at about $61,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Vanda Pharmaceuticals by 18.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 2,425 shares in the last quarter. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently issued reports on VNDA. Cantor Fitzgerald raised their price objective on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. StockNews.com began coverage on shares of Vanda Pharmaceuticals in a research note on Monday. They set a “hold” rating for the company.

Vanda Pharmaceuticals Trading Down 3.2 %

Shares of VNDA stock opened at $4.54 on Wednesday. Vanda Pharmaceuticals Inc. has a 1-year low of $3.30 and a 1-year high of $6.75. The stock has a market cap of $264.64 million, a price-to-earnings ratio of -56.75 and a beta of 0.77. The stock has a 50-day moving average of $5.25 and a 200-day moving average of $5.17.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. The firm had revenue of $50.47 million for the quarter. Sell-side analysts forecast that Vanda Pharmaceuticals Inc. will post -0.49 earnings per share for the current year.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.